Protalix BioTherapeutics (PLX) FCF Margin (2010 - 2026)
Protalix BioTherapeutics' quarterly FCF Margin came in at 64.41% in Q1 2026, up 11865.0% year-on-year from N/an in Q1 2025, and up 102.89% quarter-over-quarter from 31.75% in Q4 2025.
Protalix BioTherapeutics has reported FCF Margin for 17 years, with the latest figure at 64.41% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin rose 11865.0% year-over-year to 64.41%; the trailing twelve-month figure through Mar 2026 stood at 19.46% (up 2055.0% YoY), and the FY2025 full-year result was 23.44%, down 3921.0% from the prior year.
- FCF Margin for Q1 2026 stood at 64.41%, up from 31.75% in the prior quarter.
- The five-year high for FCF Margin was 95.78% in Q1 2024, with the low at 82.35% in Q2 2022.
- Average FCF Margin over 5 years is 10.01%, with a median of 23.7% recorded in 2025.
- Year-over-year, FCF Margin sank 17936 bps in 2022 and jumped 12964 bps in 2024.
- Tracing PLX's FCF Margin over 5 years: stood at 29.58% in 2022, then surged by 204 bps to 30.84% in 2023, then decreased by 18 bps to 25.22% in 2024, then gained by 26 bps to 31.75% in 2025, then jumped by 103 bps to 64.41% in 2026.
- The last three FCF Margin figures came in at 64.41% (Q1 2026), 31.75% (Q4 2025), and 23.7% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.17% |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 64.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 64.41% |
| Dec 31, 2025 | 31.75% |
| Sep 30, 2025 | -23.70% |
| Jun 30, 2025 | -35.40% |
| Mar 31, 2025 | -54.24% |
| Dec 31, 2024 | 25.22% |
| Sep 30, 2024 | 18.76% |
| Jun 30, 2024 | -23.25% |
| Mar 31, 2024 | 95.78% |
| Dec 31, 2023 | 30.84% |
| Sep 30, 2023 | -64.66% |
| Jun 30, 2023 | 13.60% |
| Mar 31, 2023 | -33.85% |
| Dec 31, 2022 | -29.58% |
| Sep 30, 2022 | -65.77% |
| Jun 30, 2022 | -82.35% |
| Mar 31, 2022 | -37.66% |
| Dec 31, 2021 | -64.74% |
| Sep 30, 2021 | -18.45% |
| Jun 30, 2021 | 97.01% |
| Mar 31, 2021 | -90.28% |
| Dec 31, 2020 | -38.40% |
| Sep 30, 2020 | -34.35% |
| Jun 30, 2020 | -73.37% |
| Mar 31, 2020 | -33.18% |
| Dec 31, 2019 | -22.79% |
| Sep 30, 2019 | -25.39% |
| Jun 30, 2019 | -42.52% |
| Mar 31, 2019 | -71.33% |
| Dec 31, 2018 | -212.47% |
| Sep 30, 2018 | 2,041.48% |
| Jun 30, 2018 | -404.24% |
| Mar 31, 2018 | -212.21% |
| Dec 31, 2017 | 967.56% |
| Sep 30, 2017 | -143.41% |
| Jun 30, 2017 | -138.72% |
| Mar 31, 2017 | -532.69% |
| Dec 31, 2016 | -358.77% |
| Sep 30, 2016 | -76.85% |
| Jun 30, 2016 | -699.43% |
| Mar 31, 2016 | -1,401.91% |
| Sep 30, 2015 | -751.05% |
| Jun 30, 2015 | -343.34% |
| Mar 31, 2015 | -370.33% |
| Mar 31, 2014 | -128.48% |
| Dec 31, 2013 | -20.85% |
| Sep 30, 2013 | -374.04% |
| Jun 30, 2013 | -389.05% |
| Mar 31, 2013 | -286.66% |
| Dec 31, 2012 | 133.96% |
| Sep 30, 2012 | -236.28% |
| Jun 30, 2012 | 49.35% |
| Mar 31, 2012 | -183.66% |
| Dec 31, 2011 | -309.74% |
| Sep 30, 2011 | -806.71% |
| Jun 30, 2011 | -816.10% |
| Mar 31, 2011 | -159.69% |
| Dec 31, 2010 | -771.26% |
| Sep 30, 2010 | -346.20% |